Compare CAAS & MSLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CAAS | MSLE |
|---|---|---|
| Founded | N/A | N/A |
| Country | China | Canada |
| Employees | N/A | 21 |
| Industry | Auto Parts:O.E.M. | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.9M | 154.6M |
| IPO Year | 2025 | N/A |
| Metric | CAAS | MSLE |
|---|---|---|
| Price | $4.35 | $9.78 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 10.4K | ★ 97.8K |
| Earning Date | 04-22-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.97 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.87 | $5.44 |
| 52 Week High | $5.15 | $13.39 |
| Indicator | CAAS | MSLE |
|---|---|---|
| Relative Strength Index (RSI) | 48.75 | 66.72 |
| Support Level | $4.33 | $6.71 |
| Resistance Level | $4.50 | $13.39 |
| Average True Range (ATR) | 0.11 | 0.82 |
| MACD | 0.01 | 0.07 |
| Stochastic Oscillator | 57.89 | 73.42 |
China Automotive Systems Inc is a holding company. The firm, through its subsidiary, is a supplier of power steering systems and components to China's automotive industry. Its product offering encompasses a full range of auto parts incorporated into steering systems for both passenger automobiles and commercial vehicles. The company offers four separate series of power steering models, including rack and pinion power steering, integral power steering, electronic power steering, steering columns, steering oil pumps, and steering hoses. Geographically, it derives a majority of its revenue from China.
Satellos Bioscience Inc is a Canadian biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation, which Satellos has identified as a root cause of the progressive nature of this disease.